Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-3242 plus lenacapavir versus Biktarvy in treatment-naive people with HIV-1
2026-526026-40-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing Injectable GS-3242 + lenacapavir regimen with Biktarvy active control (2 arms). Planned start Oct 2026; status: authorised.
02
Drugs
GS-3242lenacapavirbictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2026-526026-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526026-40-00.